Healthcare provider profile · identity verified

Andrew Edward Short, MD

Family Practice · BROOMALL, PA · NPI 1669900304

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	293	116
Amlodipine Besylate	Amlodipine Besylate	251	83
Levothyroxine Sodium	Levothyroxine Sodium	155	52
Rosuvastatin Calcium	Rosuvastatin Calcium	141	56
Losartan Potassium	Losartan Potassium	129	42
Lisinopril	Lisinopril	126	42
Alprazolam	Alprazolam	98	25
Gabapentin	Gabapentin	98	30
Metformin Hcl	Metformin Hcl	97	35
Tamsulosin Hcl	Tamsulosin Hcl	90	34
Hydrochlorothiazide	Hydrochlorothiazide	87	29
Omeprazole	Omeprazole	82	28
Metoprolol Succinate	Metoprolol Succinate	69	30
Pantoprazole Sodium	Pantoprazole Sodium	69	27
Simvastatin	Simvastatin	69	25
Zolpidem Tartrate	Zolpidem Tartrate	61	16
Synthroid	Levothyroxine Sodium	55	16
Eliquis	Apixaban	53	12
Escitalopram Oxalate	Escitalopram Oxalate	44	18
Trazodone Hcl	Trazodone Hcl	44	23
Duloxetine Hcl	Duloxetine Hcl	43	17
Carvedilol	Carvedilol	42	14
Lorazepam	Lorazepam	42	16
Valsartan	Valsartan	42	20
Montelukast Sodium	Montelukast Sodium	40	24
Prednisone	Prednisone	40	30
Ozempic	Semaglutide	37	suppressed
Ezetimibe	Ezetimibe	34	11
Oxycodone Hcl	Oxycodone Hcl	34	suppressed
Potassium Chloride	Potassium Chloride	33	suppressed
Sertraline Hcl	Sertraline Hcl	32	17
Glimepiride	Glimepiride	31	suppressed
Fluticasone Propionate	Fluticasone Propionate	30	14
Furosemide	Furosemide	30	11
Jardiance	Empagliflozin	30	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	29	12
Doxycycline Hyclate	Doxycycline Hyclate	28	23
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	28	23
Albuterol Sulfate Hfa	Albuterol Sulfate	27	15
Famotidine	Famotidine	27	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	25	24
Clonazepam	Clonazepam	25	suppressed
Bupropion Xl	Bupropion Hcl	24	suppressed
Clopidogrel	Clopidogrel Bisulfate	23	suppressed
Mirtazapine	Mirtazapine	23	suppressed
Allopurinol	Allopurinol	22	suppressed
Diazepam	Diazepam	22	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	22	suppressed
Amoxicillin	Amoxicillin	21	18
Azithromycin	Azithromycin	21	19
Metformin Hcl Er	Metformin Hcl	21	suppressed
Pravastatin Sodium	Pravastatin Sodium	21	suppressed
Pregabalin	Pregabalin	19	suppressed
Valacyclovir	Valacyclovir Hcl	19	12
Metoprolol Tartrate	Metoprolol Tartrate	18	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	18	suppressed
Ipratropium Bromide	Ipratropium Bromide	17	suppressed
Nystatin	Nystatin	17	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	16	suppressed
Meloxicam	Meloxicam	16	14
Ramipril	Ramipril	16	suppressed
Tramadol Hcl	Tramadol Hcl	16	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	16	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	15	suppressed
Enalapril Maleate	Enalapril Maleate	14	suppressed
Mounjaro	Tirzepatide	14	suppressed
Clonidine Hcl	Clonidine Hcl	13	suppressed
Clotrimazole	Clotrimazole	13	suppressed
Memantine Hcl	Memantine Hcl	13	suppressed
Methenamine Hippurate	Methenamine Hippurate	13	suppressed
Mycophenolate Mofetil	Mycophenolate Mofetil	13	suppressed
Ondansetron Odt	Ondansetron	13	suppressed
Propranolol Hcl	Propranolol Hcl	13	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	13	suppressed
Diovan	Valsartan	12	suppressed
Finasteride	Finasteride	12	suppressed
Glipizide	Glipizide	12	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	12	suppressed
Spiriva Respimat	Tiotropium Bromide	12	suppressed
Azelastine Hcl	Azelastine Hcl	11	suppressed
Buspirone Hcl	Buspirone Hcl	11	suppressed
Celecoxib	Celecoxib	11	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	11	suppressed
Ketoconazole	Ketoconazole	11	suppressed
Midodrine Hcl	Midodrine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error